About palvella therapeutics - PVLA
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. It develops a pipeline of treatments for rare genetic skin diseases using its patented QTORIN platform. The company was founded in 2015 and is headquartered in Wayne, PA.
PVLA At a Glance
Palvella Therapeutics, Inc.
125 Strafford Avenue
Wayne, Pennsylvania 19087
| Phone | 1-484-253-1461 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -17,434,000.00 | |
| Sector | Health Technology | Employees | 14 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
PVLA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 2.111 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 3.189 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.266 |
PVLA Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,245,285.714 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
PVLA Liquidity
| Current Ratio | 7.33 |
| Quick Ratio | 7.33 |
| Cash Ratio | 6.945 |
PVLA Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -27.474 |
| Return on Equity | -39.018 |
| Return on Total Capital | -23.386 |
| Return on Invested Capital | -34.418 |
PVLA Capital Structure
| Total Debt to Total Equity | 19.075 |
| Total Debt to Total Capital | 16.019 |
| Total Debt to Total Assets | 13.534 |
| Long-Term Debt to Equity | 19.075 |
| Long-Term Debt to Total Capital | 16.019 |